Title
Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications.

Permalink
https://escholarship.org/uc/item/6xc6n5hk

Journal
Frontiers in oncology, 9

ISSN
2234-943X

Authors
Ryan, Matthew J
Bose, Rohit

Publication Date
2019

DOI
10.3389/fonc.2019.01287

Peer reviewed
Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications

Matthew J. Ryan1,2,3 and Rohit Bose2,3,4,5,6*

1 Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA, United States, 2 Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, United States, 3 Department of Anatomy, University of California, San Francisco, San Francisco, CA, United States, 4 Departments of Medicine and Urology, University of California, San Francisco, San Francisco, CA, United States, 5 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States, 6 UCSF Benioff Initiative for Prostate Cancer Research, San Francisco, CA, United States

The increasing number of patients with sequenced prostate cancer genomes enables us to study not only individual oncogenic mutations, but also capture the global burden of genomic alterations. Here we review the extent of tumor genome mutations and chromosomal structural variants in various clinical states of prostate cancer, and the related prognostic information. Next, we discuss the underlying mutational processes that give rise to these various alterations, and their relationship to the various molecular subtypes of prostate cancer. Finally, we examine the relationships between the tumor mutation burden of castration-resistant prostate cancer, DNA repair defects, and response to immune checkpoint inhibitor therapy.

Keywords: prostate cancer, tumor mutation burden, copy number alteration, structural variants, aneuploidy, mismatch repair deficiency, immune checkpoint inhibitor

INTRODUCTION

Prostate cancer is the second-most common cancer in men worldwide (1), and advanced forms of the disease cause debilitating bone pain, pathologic fractures, and severe anemia. The era of profiling patients’ tumors using next generation sequencing (NGS) has yielded both scientific and clinical advances including: the comprehensive detection of BRCA mutations for PARP inhibitor therapy; the identification of poorer prognosis RB1 mutations; and the full extent of AR genomic alterations associated with androgen receptor signaling inhibitor (ARSI) resistance (2–6). Equally important, NGS profiling has expanded our insight beyond a handful of known loci to capture our first snapshots of the prostate tumor genome in its entirety. This raises the question: does the global burden of mutations and chromosomal structural variants reveal information beyond individual driver mutation analysis?

Here we examine the genomic alteration burden in various states of prostate cancer, a disease with a heterogenous clinical course. Next, we delve into the various mutational processes underlying those alterations and highlight associations with molecular subtypes. Finally, we evaluate how a tumor’s mutation burden may help predict response to certain therapies. There are several caveats: factors beyond the tumor genome, such as the transcriptome, epigenome, and the microenvironment are undoubtedly relevant, but beyond the scope of this mini review. Secondly, the analyzed cohorts are predominantly comprised of patients of European ancestry. Finally, this review of global genomic alterations is simply designed to augment, not supersede, the relevance of individual mutations and traditional clinical parameters.
BURDEN OF GENOMIC ALTERATIONS IN DIFFERENT CLINICAL STATES

Tumor mutation burden (TMB) (7) is measured differently among various prostate cancer cohorts. Sometimes, it is reported as the load of non-synonymous mutations (NS) with a minimum allele frequency of 0.5–10%. Other times, it is reported as the load of any single nucleotide variants (SNVs). Some studies additionally report the rate of indels (8, 9). The TMB of unselected and usually treatment-naïve locoregional prostate adenocarcinoma cohorts typically falls between 0.94 and 1.74 NS per megabase (Mb) (Table 1). Average TMB appears to correlate with the patient’s age at diagnosis (∼0.5 NS/Mb for those diagnosed in their 40s vs. ∼0.9 NS/Mb in their 60s) (12). Primary tumor grade is a major clinical feature and described by the Gleason score (currently being updated to the Grade Group system) (33). The SNV burden has been reported as 1.5× higher in intermediate pattern Gleason 7 tumors vs. well-differentiated pattern Gleason 6 tumors (p = 1.05 × 10−3) (16), consistent with other reports (12). Interestingly, a small cohort of South African patients of African ancestry with high-risk locoregional disease were found to have a roughly 4-fold increase of TMB (3.0–4.7 SNVs plus indels/Mb) (Table 1) compared with a control cohort of European ancestry (23). On the other hand, a study of African-American men with primary prostate cancer had a rate of 0.83 SNVs/Mb, in line with cohorts of predominantly European-Americans (17).

Prostate cancer that presents as de novo metastases, or reappears as macro-metastases following definitive prostatectomy/radiotherapy, is termed metastatic castration-sensitive prostate cancer (mCSPC) (34–36). Just as the pattern of individual mutations is similar between locoregional disease and mCSPC, so is the mean TMB (1.74 vs. 2.08 NS/Mb) (13). Likewise, a separate study showed that patients presenting with markedly elevated PSA (≥15) and a biopsied MRI-positive primary lesion had no significant TMB difference compared to those found to have mCSPC disease (20). However, as the disease advances beyond mCSPC, so too does the TMB. Metastatic castration-resistant prostate cancer (mCRPC) can no longer be controlled with androgen ablation and is the most morbid and lethal clinical state. Several groups have noted that the TMB of mCRPC is accordingly increased (4.02 vs. 2.08 NS/Mb in mCSPC in one study) (Table 1) (13, 18, 27, 29, 31).

However, analyzing prostate tumor genomes solely via TMB misses many alterations, since the disease has a higher burden than many other cancers of chromosomal structural variants including insertions, deletions, inversions, translocations, gene-fusions, and tandem duplications (14, 37, 38). Locoregional prostate cancer cohorts have a highly variable structural variant burden, with a median of 19 structural variants per genome (range between 0 and 499, Table 2) (16). Like TMB, the structural variant burden correlates with Gleason score (17 in Gleason 6 disease compared to 22 in Gleason 7, p < 0.001) (Table 2) (16). The mCRPC cohorts have a much higher structural variant burden than in locoregional disease; median lies between 230 and 337 per study (Table 2), keeping in mind structural variant measurement is not standardized (9, 28, 29).

At the chromosomal level, mCRPC genomes frequently demonstrate polyploidy and/or aneuploidy. There are several NGS studies confirming that roughly ≥40% of mCRPC samples are triploid or more (9, 27, 43), a status itself associated with more translocations and SNVs (9). Regarding aneuploidy, about 75% of locoregional prostate cancer genomes have chromosomal arm-level alterations, and 23% possessed ≥5 arm-level alterations (44). As with TMB and structural variants, the degree of arm-level alterations correlates with Gleason score: only ∼3% of Gleason 6 tumors have ≥5 arm-level alterations compared to ∼40% of the very poorly differentiated Gleason 9–10 tumors. Even after adjusting for Gleason score, the degree of tumor aneuploidy predicted future lethal prostate cancer risk with a median follow-up of 15 years: patients with ≥5 arm-level alterations had a odds ratio for lethality of 5.34 (95% CI 2.18–13.1) compared with those with no aneuploidy (44).

The majority of NGS-based clinical testing involves targeted panels, rather than whole genome sequencing (WGS), making direct detection of some structural variants challenging. However, copy number alterations (CNA) of individual genes and genomic regions can be robustly detected, and they are an indirect measure of unbalanced structural variants and aneuploidy. The tumor CNA burden (TCB) is reported as the fraction of the measured genome with broad CNA. The median TCB of locoregional disease is ∼7% of the genome altered (12, 13, 45). TCB differs statistically with age at diagnosis and Gleason score in a similar way to TMB: those diagnosed in their 40s have a median TCB of ∼2% genome altered whereas those diagnosed in their 60s have ∼9% altered (12). Gleason 6 tumors have median TCBS of ∼1% genome altered, whereas Gleason ≥8 tumors have ∼13% altered (12), consistent with other reports (46). The TCB of tumors confers considerable prognostic information (43, 45, 47, 48): it is significantly associated with biochemical recurrence (each 1% increase in TCB was associated with a 5–8% decrease in 5-years relapse-free survival) and future metastasis (45). This was independently verified (43), even after adjustment for Gleason score and TMB (47). TCB was also found to be associated with prostate cancer-specific death after adjustment for clinical parameters, such as CAPRA (Cancer of the Prostate Risk Assessment) score (49) or Gleason score (per 5% TCB, HR 1.49; 95% CI 1.30–1.70) (47). Unlike TMB, median TCB of mCSPC tumors is higher than locoregional disease (20–30% genome altered) and even higher in mCRPC tumors (cohort medians between 23 and ∼38%) (9, 12, 13, 20, 24). TCB is negatively associated with overall survival in metastatic tumors in multivariate analysis even after adjustment for TMB (per 5% TCB, HR = 1.08; 95% CI 1.02–1.15) (47).

There is a subset of prostate cancer that emerges clinically in the treated mCRPC state, whereby the dominant metastatic histology is now either small-cell carcinoma or possesses neuroendocrine features. This treatment-emergent small-cell/neuroendocrine prostate cancer (t-SCNC) (30, 50) has both characteristic molecular and aggressive clinical features; there is an enrichment for RB1/TP53 genomic alterations and rapidly progressive visceral metastases. In one analysis, there were no statistically significant differences between TMB, TCB, or ploidy between t-SCNC vs. mCRPC adenocarcinoma (30).
This is consistent with the postulation that neuroendocrine transdifferentiation may be driven substantially by epigenetic mechanisms (51).

Longitudinal analysis of prostate tumor genomes reveals further complexity in interpreting TMB and TCB, since mutational processes are dynamic, interrelated, can arise in a multi-focal setting, and evolve with different degrees of clonality (13, 31, 46, 52). One study reports that 40% of primary prostate tumors appear to be monoclonal i.e., one dominant clone is detected (46). The remaining 60% of primary tumors demonstrate subclonal populations (78% biclonal, 20% triclonal) originating from an ancestral clone. These polyclonal tumors have inferior clinical outcomes with respect to biochemical relapse following definitive prostatectomy/radiotherapy (HR 2.64; CI 1.36–5.15), and persisting after adjustment for standard clinical parameters and TCB (46). The polyclonality-related

### Table 1: Tumor mutation burden (TMB) in locoregional, metastatic castration-sensitive (mCSPC), and metastatic castration-resistant (mCRPC) prostate cancer samples.

| Clinical state | TMB (mutations per Mb or sample) | Method of sequencing | Algorithm for somatic mutation calling | Cohort (number of samples) | References |
|----------------|----------------------------------|---------------------|--------------------------------------|-----------------------------|------------|
| Locoregional   | 0.94 NS/Mb<sup>b</sup>           | WES                 | MuTect (10)                          | TCGA, Cell 2015 (n = 333)   | (11)       |
|                | 1.36 NS/Mb<sup>c</sup>           | WES                 | MuTect (10)                          | MSKCC/DFCI, Nature Genetics 2018 (n = 1013) | (12)       |
|                | 1.74 NS/Mb<sup>d</sup>           | Gene panel (MSK-IMPACT)<sup>a</sup> | MuTect (10) | MSKCC, JCO Precis Oncol 2017 (n = 504) | (13)       |
|                | 33 NS/sample<sup>c</sup>         | WGS                 | MuTect (10)                          | Broad/Cornell, Cell 2013 (n = 57) | (14)       |
|                | 0.53 SNVs/Mb<sup>b</sup>         | WGS                 | SomaticSniper (15)                   | CPC-GENE, Nature 2017 (n = 477) | (16)       |
|                | 0.83 SNVs/Mb<sup>b</sup>         | WES                 | MuTect (10)                          | Cornell/Karmanos, Cancer Discov 2017 (n = 102) | (17)       |
|                | 0.93 SNVs/Mb<sup>c</sup>         | WES                 | Used own method                      | mCSP, Nature 2012 (n = 61) | (18)       |
|                | 0.93 SNVs/Mb<sup>d</sup>         | WES                 | VarScan (19)                         | PROGENY Study, Ann Oncol 2017 (n = 49) | (20)       |
|                | 1.4 SNVs/Mb<sup>b</sup>          | WES                 | MuTect (10)                          | Broad/Cornell, Nat Genet 2012 (n = 112) | (21)       |
| mCSPC          | 3.0–4.7 SNVs plus indels/Mb      | WGS                 | MuTect, Streika, VarScan (10, 19, 22) | SAPCS, Cancer Res 2018 (n = 15) | (23)       |
|                | 2.08 NS/Mb<sup>f</sup>           | Gene panel (MSK-IMPACT)<sup>a</sup> | MuTect (10)                          | MSKCC, JCO Precis Oncol 2017 (n = 504) | (13)       |
| mCRPC          | 4.02 NS/Mb<sup>f</sup>           | Gene panel (MSK-IMPACT)<sup>a</sup> | MuTect (10)                          | MSKCC, JCO Precis Oncol 2017 (n = 504) | (13)       |
|                | 4.1 NS/Mb<sup>b</sup>            | WGS                 | MuTect, Streika (10, 22)             | SU2C/PCF Dream Team, Cell 2018 (n = 101) | (9)        |
|                | 44 NS/sample<sup>c</sup>         | WES                 | Used Own Method                      | Fred Hutchinson CRC, Nat Med 2016 (n = 176) | (24)       |
|                | 2.00 SNVs/Mb<sup>c</sup>         | WES                 | Used Own Method                      | mCSP, Nature 2012 (n = 61) | (18)       |
|                | 2.3 SNVs/Mb<sup>c</sup>          | WGS                 | Freebayes, Pindel (25, 26)           | UMichigan, Cell 2018 (n = 380) | (25)       |
|                | 3.6 SNVs/Mb<sup>c</sup>          | WGS                 | MuTect (10)                          | MSKCC/DFCI, SU2C/PCF Dream Team, Cell 2018 (n = 23) | (26)       |
|                | 4.4 SNVs/Mb<sup>c</sup>          | WES                 | MuTect (10)                          | SU2C/PCF Dream Team, Cell 2015 (n = 150) | (29)       |
|                | 41 SNVs/sample<sup>b</sup>       | WES                 | MuTect (10)                          | Multi-Institute, Nat Med 2016 (n = 114) | (30)       |
|                | 98 SNVs/sample<sup>b</sup>       | WGS                 | CaVEMan (31)                         | PELICAN Study, Nature 2015 (n = 10) | (31)       |

<sup>a</sup>TCGA, The Cancer Genome Atlas; MSKCC, Memorial Sloan Kettering Cancer Center; DFCI, Dana-Farber Cancer Institute; PROGENY, PROstate cancer GENomic heterogeneity; CPC-GENE, Canadian Prostate Cancer Genome Network; SAPCS, Southern African Prostate Cancer Study; MCTP, Medicaid Cancer Treatment Program; SU2C, Stand Up to Cancer; PCF, Prostate Cancer Foundation; CRC, Cancer Research Center; PELICAN, Project to ELIminate lethal CANcer.

<sup>b</sup>These are median values as reported.

<sup>c</sup>These are mean values as reported.

<sup>d</sup>Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) is a targeted panel (32).

<sup>e</sup>The human genome is ~3 Gb. The exome is about 1% of the genome, or ~30 Mb.

<sup>f</sup>Many samples in this cohort are neuroendocrine prostate cancer, rather than prostate adenocarcinoma.
risk appears to be additive to those derived from the combination of TMB and TCB. Interestingly, triclinal tumors have a higher median PSA level at diagnosis (9.7 vs. ~7 for monoclonal/biclonal; \( p < 0.01 \)), and polyclonal primary tumors are also more likely to develop metastases later on (OR = 4.01; \( p < 0.05 \)). In polyclonal primary tumors, most of the TMB is truncal (median 87% of total SNVs) whereas the TCB is more evenly distributed between being truncal (55%) vs. branch-specific (45%). Moreover, the individual truncal CNAs are larger (median 11.5 vs. 6.5 Mb for branch-specific CNAs) and biased toward deletions (84% of all deletions are truncal). CNAs are also observed at chromosome ends, and the median telomere length of polyclonal tumors is 500 bp shorter than monoclonal tumors (46).

Altogether, the burden of genomic alterations correlates with key clinical information for prostate cancer patients. The TMB, structural variants, and TCB all tend to increase with advancing clinical state, Gleason score, and age. However, clonality analysis hints that how these mutational processes combine during tumor evolution is quite complex.

**MUTATIONAL PROCESSES UNDERLYING PROSTATE CANCER GENOMIC ALTERATIONS**

Next, we examine the biologic processes that generate these genomic alterations, starting with SNVs. Comparison of tumor-derived patterns of SNVs within their trinucleotide context to pre-defined signatures (53) can suggest the underlying etiology; for example, cancers with known exogenous risk factors reveal robust signatures associated with tobacco or UV exposure. However, the majority of mCRPC tumors with intact DNA repair pathways reveal a robust signature that is endogenous, age-related and likely results from deamination of 5-methylcytosine to thymine at mCpG dinucleotides (COSMIC signature 1) (12, 54). If not repaired before DNA replication, this results in a permanent C > T transition. This signature is contributory in most cancer types and the frequency of associated SNVs correlates with the age at diagnosis in pan-cancer analysis, although not necessarily meeting statistical significance when analyzing each tissue individually (54). Nevertheless, the rate of prostate cancer SNVs attributed to this age-related signature loosely fits a slope of ~6 SNVs/Gb/year and may contribute to the increased TMB of patients diagnosed at older ages. Clonality analysis reveals that this age-related signature is most dominant early in prostate tumor evolution (46).

In prostate tumors possessing DNA repair defects, SNVs are associated with different dominant signatures. A recent NGS analysis of one cohort revealed 3% of genomes possess somatic DNA mismatch repair defects (MMRD) (55) caused by loss-of-function mutations in the canonical genes MLH1, MSH2, MSH6, or PMS2, and consistent with other cohorts (56–58). If one of the allelic mutations is germline, the patient has Lynch syndrome and possesses increased lifetime risk for several cancer types including prostate cancer (59, 60). These tumor genomes are 10- to 100-fold less likely to repair base pair substitutions prior to DNA replication, and their TMB is elevated (20–80 SNVs/Mb in mCRPC) although not necessarily as high as other MMRD cancer types (29). Analysis as above reveals dominant SNV signatures associated with MMRD, as expected (9, 27, 55, 61). MMRD tumors also possess high rates of indels (9), leading to higher instability of DNA microsatellite lengths, a way in which such tumors can be detected (55). MMRD tumors have distinct genomes from those that are MMR proficient: they are usually diploid, and have the lowest TCB (27). We further discuss MMRD tumors in the next section.

A third class of SNVs is observed in tumors with homologous recombination deficiency (HRD) from 6 to 20% of patients with either somatic or germline alterations of BRCA1 or BRCA2, frequently biallelic (9, 13, 27, 29, 62). Since DNA homologous recombination coordinates the repair of double stranded DNA breaks, HRD not only results in a high TCB, but also a reliance on alternative error-prone DNA repair pathways (63) and a distinct dominant group of SNV signatures (9, 27). Accordingly, BRCA-mutant tumors in mCRPC possess the highest SNV rate among MMR proficient tumors (7.0 muts/Mb), in addition to higher TCB (9).

---

**TABLE 2 | Structural variant burden (SVB) in locoregional and mCRPC samples.**

| Clinical state | Structural variant burden (SVs per sample) | Method of determining SVs | Cohort* | References |
|---------------|------------------------------------------|--------------------------|---------|------------|
| Locoregional  | 19 SVs/sample\(^{a,c}\)                | Delly v0.5.5 (53)         | CPC-GENE, Nature 2017 (\( n = 477 \)) | (16) |
| mCRPC         | 230 SVs/sample\(^{a,d}\)               | SvABA (43); GROCSSV (41); Long Ranger v2.1.2 (https://support.10xgenomics.com/genome-exome/software/pipelines/latest/using/wgs) | MSKCC/DFCI, SU2C/PCF Dream Team, Cell 2018 (\( n = 23 \)) | (23) |
|               | 337 SVs/sample\(^{a,c}\)               | Manta v1.1.1 (42)         | SU2C/PCF Dream Team, Cell 2018 (\( n = 101 \)) | (9) |

*\(^{a}\)CPC-GENE, Canadian Prostate Cancer Genome Network; MSKCC, Memorial Sloan Kettering Cancer Center; DFCI, Dana-Farber Cancer Institute; SU2C, Stand Up to Cancer; PCF, Prostate Cancer Foundation.

*\(^{c}\)These are median values as reported.

*\(^{d}\)The human genome is ∼3 Gb, of which the exome is about 1%, or ∼30 Mb.

*\(^{e}\)These are mean values as reported.

---
There are other SNV signatures observed to varying degrees in prostate tumors, some of which have not yet been associated with an etiology (27, 53). Moreover, SNVs are not evenly distributed throughout a given tumor’s genome, but rather dependent on many interrelated factors, including the underlying mutational process, the timing of the locus within DNA replication, as well as whether the locus affects transcription and/or translation. The phenomenon of localized regions of SNV-based hypermutation is called kataegis, and is found in 23% of primary tumors (16); it is coincident with genomic instability, likely altered DNA repair (64), and enriched for deletions of the chromatin remodeler CHD1 (33% of kataegis-positive tumors compared with only 11% of kataegis-null tumors) (16). Kataegis is associated with increasing Gleason score, and present in 40% of Gleason 4+3 tumors.

Just as specific processes lead to increased TMB, others lead to increased TCB. For example, BRCA-mutant tumors have markedly higher frequencies of copy number deletions as well as classic genomic “scars” due to their HRD (9). On the other hand, specifically in HR proficient tumors, chromothripsis can occur: evidence of “shattering” of regions in one or a few chromosomes followed by intrachromosomal reassembly in a stochastic manner, resulting in large numbers of both deletions and inversions (9). It is found in 20% of non-indolent primary prostate cancer samples (16) and 23% of mCRPC samples (9). Although the exact mechanism is unknown, there are some clear correlations: chromothripsis positive genomes are enriched for biallelic TP53 loss (83% of chromothripsis positive tumors vs. 35% of chromothripsis null tumors), although this event is not likely sufficient to cause chromothripsis (9, 16). Others have noted a correlation between genomic loss of CHD1 and chromothripsis (14). From a clinical standpoint, chromothripsis is associated with the primary tumor T-stage, but was not found to differ by age or Gleason grade (16).

About 5% of mCRPC cases have a significantly higher number of genomic tandem duplications, and 90% of these genomes have biallelic CDK12 alterations (27, 28). In such cases there is a median of 150 tandem duplications per sample with a median duplicated region size of 1.3 Mb (28). Accordingly, such tumors possess large numbers of focal CNAs, and also have the highest gene-fusion burden (100 per tumor vs. 25 in other tumors), due directly to the genomic duplication phenomenon (27). CDK12-mutant tumors are usually diploid and trend toward mutual exclusivity from HRD biallelic BRCA-mutant tumors (9). Clonality analysis reveals that CDK12 alterations are usually truncal; in these samples, the accompanying SNVs are more likely to occur after tandem duplication than before, and in many cases in branch-specific subclones (28). It is unknown whether CDK12 alterations directly cause the tandem duplications, or are merely associated with it, but there is evidence to support the former (28).

Finally, some mutational processes occur without directly affecting TMB or TCB. The most common gene fusions in prostate cancer occur between androgen-driven upstream elements of genes like TMPRSS2, and oncogenic ETS transcription factors like ERG, and are present in up to 50–60% of men of European descent (65). The underlying chromosomal rearrangements that cause such gene fusions are initially balanced, frequently complex and involve multiple chromosomes in a phenomenon termed chromoplexy (14). Some degree of chromoplexy is present in 50–90% prostate tumors (9, 14). Moreover, in tumors possessing ETS gene fusions, the chromoplexy has more than double the number of interchromosomal rearrangements compared to ETS fusion-null tumors (14). There is evidence of successive rounds of chromoplexy occurring, for example initially leading to ETS fusion formation, and then subsequently to inactivation of tumor suppressor genes. It is not known exactly how chromoplexy occurs; there is no enrichment for TP53 mutations in such tumors, but the process may be related to androgen-related chromatin configuration (9, 14). Notably, the small cohort of South African men possessed lower frequencies of larger genomic rearrangements, such as chromothripsis and chromoplexy, and lower frequencies of ETS gene fusions, than the comparable cohort with European ancestry (23).

In summary, we have just begun to understand the processes that contribute to the burden of prostate cancer genomic alterations. SNVs possess distinct mutational signatures including those associated with aging and DNA repair defects; moreover, many tumor genomes have localized hypermutated regions. Complex chromosomal alterations, such as chromothripsis, tandem duplication, and chromoplexy tend to stratify by specific alterations in TP53, CHD1, CDK12, and BRCA1/2 and underlie many CNAs and fusion events, such as the canonical TMPRSS2-ERG fusion.

PROSTATE TUMOR MUTATION BURDEN, DNA REPAIR DEFECTS, AND THERAPEUTIC RESPONSE

The initial trials of immune checkpoint inhibitors in unselected prostate cancer patients (66–68) demonstrated no global clinical benefit in prostate cancer. Nevertheless, interest in such therapies remained strong, given case reports of impressive and durable responses among individual prostate cancer patients (69, 70). Experiences from other tumor types illuminated patient subtypes that may derive clinical benefit from existing therapies. Efforts to identify a specific predictive biomarker, such as PD-L1 expression have been challenging (71, 72); however, the association with global genomic processes has been clear. Patients with non-small cell lung cancers (73), bladder cancers (74), and melanoma (75–77) that have a high TMB derive increased clinical benefit to immune checkpoint inhibitors compared to those with low TMB. There are markedly different numerical thresholds of what constitutes a high TMB, with the highest quintile within a given histology usually being associated with longer overall survival when treated with immune checkpoint inhibitors (78). Increased non-synonymous mutations and indel frameshifts lead to increased neoepitopes within MHC Class I-loaded peptides and it is hypothesized these serve as neoantigens in the context of immunotherapy (79–84). Ongoing prostate cancer immunotherapy trials are now beginning to incorporate TMB analyses (85).
As described above, the prostate tumors with the highest TMB are those with MMRD. A series of trials treating patients with MMRD tumors with pembrolizumab, regardless of histology, reported a 53% objective radiographic response rate, and a 21% complete response rate (86). This led to the FDA approval of pembrolizumab for any MMRD metastatic/unresectable solid tumors and reinforces the importance of testing such prostate cancer patients for MMRD. In a recent study of mCRPC patients with MMRD tumors and treated with immune checkpoint inhibitors, 55% achieved a PSA response >50%, and 45% of patients had durable clinical benefit (55). A smaller study revealed that three out of four patients with MMRD tumors achieved soft tissue tumor responses upon treatment with immune checkpoint inhibitors (56). In a separate large analysis of mCRPC samples, MMRD tumors were predicted to have median neoantigen burdens of ~10,000 vs. 1,000 in MMR proficient tumors (27). Approximately 10% of these are further predicted to be “strong binders” of MHC Class I. MMRD prostate tumors were also found to have high degrees of immune infiltration (20, 27), the highest number of T-cell clonotypes, and the highest percent of expanded T-cell clones (27). Other studies have showed a complex relationship between predicted neoantigen load with immune infiltration (20), as well as considerable heterogeneity of tumor T-cell infiltration in MMRD cases (87). The exact mechanism of how predicted neoantigens stimulate a clinically-relevant immunologic response, and how this might inform the next generation of immunotherapies remains an active area of study (77).

Prostate tumors with MMRD may have other unique molecular and biological features, compared to MMR proficient disease. One case series reported an enrichment of MMRD among ductal adenocarcinoma of the prostate, a rare aggressive subtype of prostate adenocarcinoma (about 3% incidence, compared to the common acinar adenocarcinoma) with poor prognosis (56, 57, 88). Ultimately, it is important to understand the natural history of prostate cancer patients with MMRD tumors, particularly prior to any potential treatment with immune checkpoint inhibitors. One study of patients with recurrent disease reports a longer progression free survival following androgen-deprivation therapy when MMRD is detected (median 66 months compared to only 27 months in MMR proficient cases), as well as longer responses to first-line ARSI agents when used (56). On the other hand, among patients with clinically aggressive tumors (56% having metastatic disease at diagnosis), a different retrospective study of clinically aggressive CRPC noted the median overall survival for the MMRD cases was significantly shorter (3.8 years from androgen ablation) than MMR proficient groups (7.0 years), in both univariate and multivariate analysis (87). The studies above cannot be directly compared, but perhaps the biologic context is key to interpreting the clinical relevance of MMRD.

Beyond MMRD, prostate cancers with other DNA damage repair defects are being explored for their responses to immunotherapies. Because CDK12-mutant tumors have increased rates of gene fusions, they possess higher predicted neoantigen burdens (median ~2,000) than other MMR proficient tumors (27). They may also possess high degrees of T cell infiltration and expanded T cell clones. These findings have led to a Phase II trial evaluating the efficiency of combination nivolumab plus ipilimumab in mCRPC patients with CDK12-mutant tumors (89). There are also several immune checkpoint inhibitor therapy combinations being explored, such as one in which the second agent, a PARP inhibitor, alters how the genome repairs itself (90). Interestingly, a recent phase Ib/2 study showed some interesting clinical responses to the combination of pembrolizumab and olaparib, despite no BRCA mutations being detected in the biopsies tested (91). Whether this clinical response is due undetected HRD, or whether the PARP inhibitor synergizes with the immune checkpoint inhibitor by altering the presented neoepitopes or an unknown mechanism remains to be determined.

While high TMB, particularly in the context of altered DNA repair, is important regarding successful immune checkpoint therapy in prostate cancer, it is certainly not the whole story. Roughly half of MMRD prostate tumors do not exhibit substantial clinical responses to such therapy despite relatively high TMB (55). Moreover, when clinical responses are observed, the TMB is often lower compared to that observed in other MMRD cancer types e.g., in a preplanned interim analysis of a small phase II mCRPC study of combination nivolumab plus ipilimumab, responses were observed in tumors above a modest TMB threshold (85). Identifying other genomic factors that modify response to immune checkpoint inhibitors and determining whether they map to specific genes and/or global processes, remains an active area of investigation. Due to NGS-based analysis of patients’ tumors, we are just beginning to obtain a comprehensive snapshot of the prostate tumor genome in differing clinical states. A deeper understanding whether and how global genomic measures, such as TMB, TCB, gene-fusion burden and clonality affect responses to targeted and immuno-therapies will help us shape future prostate cancer investigations.

AUTHOR CONTRIBUTIONS
MR and RB drafted, revised, and approved the submitted version.

FUNDING
RB was supported by grants from the Department of Defense (W81XWH1510277), NCI (1K08CA226348), Prostate Cancer Foundation, and UCSF Benioff Initiative for Prostate Cancer Research.

ACKNOWLEDGMENTS
We thank Rahul Aggarwal, Joshua Armenia, Terence Friedlander, Andrew Hsieh, David Quigley, Sumit Subudhi, and members of the Bose laboratory for their insightful comments.
REFERENCES

1. Center MM, Jemal A, Lorret-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. *Eur Urol*. (2012) 61:1077–82. doi: 10.1016/j.euro.2012.02.054.
2. Mateo J, Carreira S, Sandhu S, Miranda S, Moseop H, Perez–Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. *N Engl J Med*. (2015) 373:1697–708. doi: 10.1056/NEJMoa1508859.
3. Abida W, Iaquinta PJ, Zhang Z, et al. Genomic hallmarks of localized, non-indolent prostate cancer. *Nat Genet*. (2019) 51:408–12. doi: 10.1038/s41588-019-0267-3.
4. Brasil CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nat Genet*. (2012) 44:685–9. doi: 10.1038/ng.2279.
5. Kumar A, Coleman I, Morrissey C, Zhang Z, True LD, Culati R, et al. Substantial interindividual and limited intranidividual genomic diversity among tumors from men with metastatic prostate cancer. *Nat Med*. (2016) 22:369–79. doi: 10.1038/nm.4053.
6. Ryan R, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. *Nat Rev Cancer*. (2015) 15:701–11. doi: 10.1038/nrc4016.
7. Adams EJ, Karthaus WR, Liu D, Gruet A, Zhang Z, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. *Nature*. (2019) 571:408–12. doi: 10.1038/s41586-019-1318-9.
8. Chun TA, Yarchan M, Jaffe E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. *Ann Oncol*. (2019) 30:44–56. doi: 10.1093/annonc/mdz249.
9. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Strelka K, et al. The Cancer Genome Atlas Pan-Cancer AVA identifies recurrent alterations across 17 cancer types. *Cell*. (2015) 163:2133–42. doi: 10.1016/j.cell.2015.10.025.
10. Cheng DT, Mitchell T, Zehir A, Shah RH, Benayed R, Syed A, et al. Integrative clinical genomics of advanced prostate cancer. *Nat Genet*. (2017) 49:1127–33. doi: 10.1038/ng.3859.
11. Ciriello G, Miller ML, Aksyov BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. *Nat Genet*. (2013) 45:1127–33. doi: 10.1038/ng.2762.
12. Crispino JB, Lassman-Stradling J, Sun Z, Storlazzi CT, Strelka K, et al. Integrative variant discovery by integrated paired-end and split-read analysis. *Bioinformatics*. (2012) 28:1333–9. doi: 10.1093/bioinformatics/bts378.
13. Dunnem G, Van Loo P, Kremer B, Alexandrov LB, Tubio JMC, Papamann E, et al. The evolutionary history of lethal metastatic prostate cancer. *Nature*. (2015) 520:353–7. doi: 10.1038/nature14347.
14. Fizazi K, Tran NP, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. *N Engl J Med*. (2015) 373:737–46. doi: 10.1056/NEJMoa1503747.
15. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. Genomic hallmarks of localized, non-indolent prostate cancer. *Nat Genet*. (2013) 45:1127–33. doi: 10.1038/ng.2762.
unstable advanced prostate cancer. Nat Commun. (2014) 5:5988. doi: 10.1038/ncomms5988

59. Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol. (2013) 31:1713–8. doi: 10.1200/JCO.2012.44.1338

60. Haroldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, et al. Prostate cancer incidence in males with Lynch syndrome. Genet Med. (2014) 16:553–7. doi: 10.1038/gim.2013.193

61. Zehir A, Benayed R, Shah RH, Syed A, Siddiqua M, Hry H, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. (2017) 23:703–13. doi: 10.1038/nm.4333

62. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. (2016) 375:443–53. doi: 10.1056/NEJMoa1603144

63. Polak P, Kim J, Brauneis L, Karlic R, Haradhalva NJ, Tiao G, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. (2017) 49:1476–86. doi: 10.1038/ng.9394

64. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. (2012) 149:979–93. doi: 10.1016/j.cell.2012.04.024

65. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun Y-W, et al. Recurrence of TMRP52 and ET5-9 transcription factor genes in prostate cancer. Science. (2005) 310:644–8. doi: 10.1126/science.1117679

66. Beer TD, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. (2019) 37:40–7. doi: 10.1200/JCO.2016.69.1584

67. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. (2014) 15:700–12. doi: 10.1016/S1470-2045(14)70189-5

68. Topalian S, Hodi F. Safety, activity, and immune correlates of anti-CTLA-4 antibody in cancer. N Engl J Med. (2012) 366:2443–54. doi: 10.1056/NEJMoa1200690

69. Cabel L, Loir E, Gravis G, Lavaud P, Massard C, Albignes L, et al. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. J Immunother Cancer. (2017) 5:1–6. doi: 10.1186/s40425-017-0223-7

70. Basnet A, Khullar G, Mehta R, Chittoria N. A case of locally advanced castration-resistant prostate cancer with remarkable response to nivolumab. Clin Genitourin Cancer. (2017) 15:6881–4. doi: 10.1016/j.clgc.2017.05.005

71. Carbone DP, Rick M, Paz-Ares L, Creelan B, Horii L, Steins M, et al. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med. (2017) 376:2415–26. doi: 10.1056/NEJMoa1613493

72. Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. (2018) 391:748–57. doi: 10.1016/s0140-6736(17)32397-X

73. Rüüvi NA, Hellmann MD, Snyder A, Kristiborg P, Makarov V, Havel JJ, et al. Genomic landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. (2015) 348:122–8. doi: 10.1126/science.aaa3148

74. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Nechiporuck C, et al. Atezolizumab for Men With Metastatic Castration-Resistant Prostate Cancer. J Urol. (2018) 200:1013–20. doi: 10.1016/j.juro.2018.05.019

75. Ryan AM, Holmgren MH, Zhang X, Smith C, Coleman I, et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite
metastatic melanoma. *Science.* (2015) 350:207–11. doi: 10.1126/science.aad0095

78. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet.* (2019) 51:202–6. doi: 10.1038/s41588-018-0312-8

79. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, et al. Cancer research. *Cancer Res.* (2008) 20:1561–72. doi: 10.1158/0008-5472.can-07-3095

80. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. *Nature.* (2012) 482:400–4. doi: 10.1038/nature10755

81. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. *J Clin Oncol.* (2013) 31:e439–42. doi: 10.1200/JCO.2012.47.7521

82. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. *Science.* (2015) 348:803–8. doi: 10.1126/science.aaa3828

83. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. *Nature.* (2014) 515:572–6. doi: 10.1038/nature14001

84. Tran E, Turcotte S, Gros A, Robbins PE, Lu Y-C, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. *Science.* (2014) 344:641–5. doi: 10.1126/science.1251102

85. Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, et al. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). *J Clin Oncol.* (2019) 37:142. doi: 10.1200/JCO.2019.37.7_suppl.142

86. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulak LH, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science.* (2017) 413:409–13. doi: 10.1126/science.aan6733

87. Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, et al. Immune-genomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. *J Clin Invest.* (2018) 128:4441–53. doi: 10.1172/JCI121924

88. Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, et al. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. *Oncotarget.* (2016) 7:82504–10. doi: 10.18632/oncotarget.12697

89. Reimers MA, Abida W, Chou J, George DJ, Heath EL, McKay RR, et al. IMPACT: immunotherapy in patients with metastatic cancers and CDK12 mutations. *J Clin Oncol.* (2019) 37: TPS5091. doi: 10.1200/JCO.2019.37.15_suppl.TPS5091

90. Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? *Nat Rev Clin Oncol.* (2018) 15:564–76. doi: 10.1038/s41571-018-0055-6

91. Yu EY, Massard C, Retz M, Tafreshi A, Carles Galceran J, Hammerer P, et al. Keynote-365 cohort A: pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). *J Clin Oncol.* (2019) 37:145. doi: 10.1200/JCO.2019.37.7_suppl.145

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2019 Ryan and Bose. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*